Biocryst Pharmaceuticals (BCRX) Capital Expenditures Growth (5y) (2015 - 2026)
Biocryst Pharmaceuticals (BCRX) Capital Expenditures Growth (5y) (2015 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Haleon | 89.55 Bn | 87.69 Bn | - |
| 2 | Teva Pharmaceutical Industries | 36.00 Bn | 32.26 Bn | 1.97 Bn |
| 3 | Zoetis | 32.59 Bn | 30.65 Bn | 1.62 Bn |
| 4 | Takeda Pharmaceutical | 27.52 Bn | 23.45 Bn | 4.39 Bn |
| 5 | United Therapeutics | 23.07 Bn | 20.91 Bn | 648.10 Mn |
| 6 | RedHill Biopharma | 21.48 Bn | 21.48 Bn | - |
| 7 | Viatris | 20.28 Bn | 18.47 Bn | 1.16 Bn |
| 8 | Neurocrine Biosciences | 17.78 Bn | 16.47 Bn | 800.70 Mn |
| 9 | Elanco Animal Health | 12.62 Bn | 12.19 Bn | 785.00 Mn |
| 10 | Biocryst Pharmaceuticals | 2.37 Bn | 2.30 Bn | 151.04 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 43.77% |
| Dec 31, 2025 | -54.58% |
| Sep 30, 2025 | 28.26% |
| Jun 30, 2025 | 72.01% |
| Dec 31, 2024 | -50.07% |
| Sep 30, 2024 | 40.16% |
| Jun 30, 2024 | -36.28% |
| Mar 31, 2024 | 20.37% |
| Dec 31, 2023 | -77.30% |
| Sep 30, 2023 | 88.93% |
| Jun 30, 2023 | 20.22% |
| Mar 31, 2023 | 35.52% |
| Dec 31, 2022 | 35.54% |
| Sep 30, 2022 | -1.53% |
| Jun 30, 2022 | 63.32% |
| Mar 31, 2022 | 166.86% |
| Dec 31, 2021 | 306.50% |
| Sep 30, 2021 | 15.32% |
| Jun 30, 2021 | -15.06% |
| Mar 31, 2021 | -50.29% |